Introduction
The Clinical and Translational Science Award (CTSA) program, supported by the NIH National Center Advancing Translational Sciences (NCATS), is comprised of approximately 60 academic medical institutions and a coordinating center working to transform the way biomedical research is conducted. The CTSA program aims to accelerate the translation of laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and translational researchers. The CTSA consortium established Strategic Goal Committees to define priorities for the consortium. The T1 Translational Research Strategic Goal Committee is focused on supporting T1 translational science 1 through the development and improvement of resources established to move discoveries (e.g., biomarkers, therapeutic agents, or medical devices) across translational barriers through to "first time in humans. " This committee established the Public Private Partnership Key Function Committee (PPP-KFC) to share best practices across the CTSAs; coordinate CTSA Consortium-wide exchange of information; identify NIH programs and initiatives that help initiate collaborations and facilitate commercialization; and provide assistance with new or established partnerships to identify partners and partnership models.
A taskforce of the Aggregating IP working group (AWG) undertook this survey to better understand how CTSA-funded institutions (e.g., Clinical Translational Science Institutes) (CTSIs) were approaching the NCATS goal of supporting new product development and to determine how these efforts were linked with those of their technology transfer offices (TTO).
Methods
The AWG taskforce created a survey for PPP-KFC members. The survey questions were developed by iterative review by the taskforce and submitted to the CTSA Consortium Coordinating Center (C4) for development into a REDCap™ database. The survey questions were divided into sections that covered organizational characteristics and relationships, the roles of the TTO and CTSI in medical product development, and models of cooperation between TTOs and CTSIs. The survey also qualitatively probed whether the programs had measureable impact on standard metrics of success (e.g., numbers of invention disclosures, licensing opportunities, and health-related start-ups). Where data were available, the AWG taskforce used the 2012 NIH Funding Database 2 and the 2011 and 2012 Association of University Technology Managers (AUTM) Surveys 3,4 as cross-references for the funding and other intellectual property (IP) metrics obtained from the survey. The data were compared by total institutional NIH funding levels, and by years of CTSA funding to evaluate trends in the programs.
The survey was distributed to the PPP-KFC membership from each of the sixty CTSA-funded institutions. The PPP-KFC members are listed on the CTSA Website. The recipients were encouraged to work jointly with their respective TTO or CTSI to ensure the accuracy of the data collection. Nonrespondents were requested to complete the survey on at least two additional occasions. Responses were analyzed by descriptive statistics. Statistical comparisons between two groups used a paired twoway Student's t-test.
For those CTSIs that reported formal collaborative programs with their TTO, the taskforce followed up with telephone interviews to collect additional information on how those projects were initiated, factors contributing to the success or failure of the programs, and the nature of the programs themselves, including types of personnel involved on project teams. An interview guide was developed by the same taskforce with questions related to the process and management of the collaborative programs. Only 4 , Nathaniel Hafer, Ph.D. 5 , and Scott Steele, Ph.D.
sites that indicated a willingness to participate in follow-up interviews were contacted by the taskforce. The data was collected individually and summarized by members of the taskforce. A total of 17 sites participated in the follow-up interviews. Responses were analyzed by descriptive statistics.
Before distribution, the survey was submitted to the University of Washington's institutional review board (IRB) with a request for designation. Based on the fact that the survey activity did not involve research with a specific hypothesis and was developed for the purpose of cataloging and investigating existing programs the IRB determined that the survey did not meet the definition of human subject's research and did not require IRB oversight.
Results

Characteristics of responding institutions
The survey was sent to 60 institutional representatives on the CTSA PPP-KFC. Responses were received from 30 of the institutions surveyed. In order to assess the generalizability of the data to all CTSA-funded institutions, the AWG taskforce compared the total 2012 NIH funding levels 2 of responder and nonresponder institutions and the timeframes in which each group joined the CTSA consortium ( Table 1) . A paired Student's t (two-tailed) of these parameters showed no difference between the responding and nonresponding sites (p value > 1.0).
Of the PPP-KFC representatives who responded to the survey, 70% identified themselves as faculty or staff affiliated with their CTSI, the remaining third with the TTO at their university. Additional TTO members contributed to institutional surveys completed by the PPP-KFC representatives. Organizationally, only one TTO (Vanderbilt University) reports directly to the principal investigator (PI) of the Vanderbilt CTSI, who is also the associate vice chancellor for research. All other TTOs are organizationally distinct from their CTSI. Five respondents identified separate initiatives within their state or institution that were developed with the express purpose of accelerating development of medical product inventions. These five institutions included Albert Einstein College of Medicine/ Montefiore Medical Center (Technology Commercialization Initiative), University of North Carolina at Chapel Hill (Carolina Kickstart), University of Alabama at Birmingham (with Southern Research Institute-Alabama Drug Discovery Alliance), Stanford University (Biodesign), and University of Pennsylvania (UPstart). More recently, the University of Rochester has established a Center for Medical Technology and Innovation (CMTI). As part of the follow-up process, these organizations/initiatives were interviewed and their involvement with CTSI's assessed.
TTO-directed product development/commercialization activities
Ninety-three percent of responding institutions stated that their TTOs consult with inventors on development strategies as a means of enhancing commercialization of the inventions resulting from university research. The TTO-directed activities supplemented the core TTO responsibilities (i.e., managing the institutional patent portfolio, filing provisional and full patent applications, negotiation of material transfer agreements, and licensing agreements), which were performed by all responding institutions. TTOs employed a variety of approaches to support product development and commercialization, summarized in Table 2 by order of frequency. A two-sided Student's t-test of each TTO-directed program was conducted to determine if the total institutional NIH funding level, used here as a surrogate measure of biomedical research activity, was a factor in determining the availability of certain programs. Only two programs segregated by this measure; conduct of market assessments and presentation to commercialization workshops. The mean NIH funding level for institutions that participated in these two activities was significantly lower than institutions that didn't provide these services (p < 0.05 for both measures). As a general trend, the year that an institution started receiving CTSA funds did not alter the type or prevalence of TTO-directed development and commercialization programs. No statistical calculations were conducted on this parameter. Activities that were less frequently available across all TTO's were more specialized and resource intensive, such as providing project management research teams, grant writers on staff, business incubators, or entrepreneur-inresidence programs.
CTSI-directed product development programs
Seventy-three percent of responding CTSIs provide product development consulting to investigators (Table 3) . Overall, most CTSIs (83%) maintain programs for clinical study implementation (e.g., clinical coordinator pools, clinical research centers, etc.). Fewer CTSIs provide the resources and expertise required for successful Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications to FDA. These less common resources include guidance on the design of nonclinical studies (60%), cGMP manufacturing facilities (40%), or GLP facilities for nonclinical studies (27%). These last two resources were found predominantly in institutions with higher levels of total NIH funding (p < 0.01). The mean funding level for institutions with GLP facilities was $306 M (n = 8) versus $179 M for those without GLP facilities (n = 22). Institutions that were early recipients of CTSA funding (2006) (2007) (2008) were more likely to provide development consultation, support IND/ IDE applications, broker industry relationships with inventors, identify funds for IND-and IDE-enabling nonclinical studies, and provide general training in medical product development. Activities that were less frequently available across all institutions were again more specialized and resource intensive, such as cGLP Animal Toxicology or project management for research teams. 
Collaborative programs between CTSI and TTO
The survey data suggests that half (50%) of the CTSI's integrate TTO staff into the CTSI-directed development programs and a slightly higher number (60%) of the TTO's integrate CTSIaffiliated staff or faculty into TTO-directed commercialization programs. Two CTSIs received funds from their TTO for one or more programs, while one TTO received funds from their CTSI. Table 4 summarizes the type of the cooperative activities and the percentage of institutions that reported having such programs in place at their institution. The collaborative programs did not segregate along NIH funding levels or years as a CTSI. As part of the survey, sites were asked to provide estimates for the total number of invention disclosures, licenses, and start-ups for 2011. The number of invention disclosures and licenses reported in the survey were consistent with published 2011 AUTM data. The sites also estimated the total number of health-related start-ups and licenses. These data were compared by presence or absence of a collaborative program with their CTSI and total NIH funding to look for trends ( Table 5 ). In all categories evaluated, TTOs that integrated the CTSI into their commercialization programs had higher licensing metrics than institutions without collaborative programs. As an example, 22 sites reported greater than five health-related licenses. Of those, 64% (n = 14) came from institutions with TTO-CTSI collaborative programs and 36% (n = 8) from institutions without collaborative programs. The commercialization data did not correlate with higher NIH funding levels or years as a CTSI (data not shown). To further explore the nature of these activities, the AWG taskforce conducted phone interviews with a total of 17 institutions reporting formal collaborative programs. These programs could be segregated into two basic types; those internal to the institutions (n = 12) and those affiliated with independent "acceleration" programs (n = 5) that were organizationally distinct from the CTSI or TTO. In some cases, the joint programs had been in existence for only six months while others had been in existence for more than 5 years. Five CTSIs have collaborative programs that have been running for 2 years or less, one for 3-4 years, while the collaborative programs at six institutions have been operating for 4 years or more. All six of these institutions had developed joint funding programs to support preclinical proof-of-concept studies.
A key factor in initiating collaborative programs at these institutions was recognition, often at the senior administrative level, that there would be benefit to the institution if the TTO and CTSI worked collaboratively. For example, at Duke University, the CTSA PI, who is also the vice chancellor for Clinical and Translational Research, initiated the effort to put collaborative programs in place, which was supported by the university chancellor and the executive director of the TTO. At Vanderbilt University, the director of the TTO, who reports to the CTSA PI, suggested the collaborative programs, which subsequently received support from the university president. At a few institutions, including University of Illinois at Chicago (UIC) and University of Washington, CTSI faculty members responsible for moving discovery research toward clinical testing approached the leadership at the TTO to begin discussions about the need for collaboration. To get these collaborative programs initiated took from several months to more than two years, depending on the difficulties in getting cooperation and buy-in. In general, efforts that started at the senior administrative level took less time to implement than when initiated by CTSI program representatives. Several respondents commented on the need to discuss common goals early in the process and both to convince the academic side of the importance of having the TTO at the table and to convince the TTO of the value of interacting with the faculty researchers at an earlier stage of their research. The three main types of collaborative programs that these institutions implemented were advisory boards for assessment of individual project goals, review committees for commercialization and translational gap awards, and individual product development teams. Some institutions have implemented all three of these programs in an integrated process, as exemplified in Figure 1 for the University of Washington CTSI, the Institute of Translational Health Sciences (ITHS).
Participatory advisory boards
In general, the goal of the advisory boards or committees, which included senior-level members from both the CTSI and the TTO, was to identify those biomedical research programs that could advance to a stage that would create more commercial value and then to facilitate the development of these opportunities, usually through various funding mechanisms. Most of the advisory boards included people with expertise in drug discovery and development, including former industry executives and directors of core facilities, such as the high throughput screening (HTS) facility, preclinical testing, medicinal chemistry, clinical research unit, and sometimes regulatory affairs. In general, the CTSI provided scientific and administrative expertise, while the TTO provided commercial and IP assessment expertise. Project managers or TTO managers also participated in the reviews.
The usual processes by which potential projects were identified included submitted proposals from a faculty researcher in response to a request-for-proposal, specific recommendations from the TTO, or a joint review of disclosures from the TTO. Specific members from the advisory boards would then work with the faculty researcher whose research looked very promising to refine a project plan and establish milestones. Funding for the project, which usually came from commercialization or translational gap funds, was generally milestone based and monitored for outcomes.
Commercialization gap funds and translational pilot funds
By and large, commercialization gap funds were managed through the TTO, while translational pilot funds were managed through the CTSI. Gap and pilot funding ranged in amount from $5,000 to $150,000 per project. For some institutions, receiving funding was tied to the formation of a product development team or regular review by an advisory committee.
The stated goals of the commercialization gap funds related primarily to making the technology more appealing for licensing or commercial investment by funding work that would reduce the risk and demonstrate initial proof-of-principle. The goals of the translational pilot funds focused on advancing the research to a more competitive position to receive external funding. In most cases, there was an advisory committee that reviewed applications for funding. Members of the CTSI and staff of the TTO frequently participated in review of applications for commercialization gap funds, but there was less frequent collaboration in the selection of awardees for CTSI-sponsored pilot funds. One example of collaborative review of CTSI pilot funds was found at Weill Cornell Medical College. During its initial funding period, the Weill Cornell CTSI PI, with the support of the dean, laid critical groundwork to support collaboration of the TTO and the CTSI. As a result this effort, the TTOs of the five Weill Cornell partner institutions work together to annually review novel technologies and select awardees with projects that offer the most translational promise.
Product development teams
Five institutions had programs that brought together a multidisciplinary development team to work with the researcher to advance the science toward commercialization. The goals generally reflected getting to a stage that allowed for commercialization or getting to the next stage of funding (e.g., SBIR, R01) or moving the project toward proof-of-principle or first-in-human testing.
The teams included a project leader, generally with industry experience; the research PI; TTO managers; people from other disciplines, such as regulatory, translational cores (e.g., HTS, preclinical testing, medicinal chemistry, statistics, bioinformatics, clinical research services); and others with expertise as needed. In some cases, investigators would include a clinician and either a basic scientist or an engineer to insure interdisciplinary and translational focus. Project leaders provided direction to the team, working closely with the research PI to think about long-term goals and to develop a plan to meet the goals. Milestones, which were generally determined as part of the competitive funding process, were established with a project leader, TTO manager, or CTSI manager, working with the PI to define them.
The interviews identified several challenges to implementing product development teams. Many of these challenges related to the relationship between the PI and the team. Some interviewees commented that investigators may have difficulty adapting to the team structure and ceding control of aspects of the project to team members. Further, because PIs had a range of academic and administrative commitments, including clinical duties for the clinical researchers and the needs of basic researchers to apply for more traditional grants, it was difficult for them to find the time to participate in team discussions. On the other hand, investigators on the teams usually became very supportive of the team approach and on occasion built it into other grants for which they were applying. Another challenge mentioned was the difficulty in finding qualified people to be project team leaders.
There was a general belief among respondents that the model of collaboration between the TTO and CTSI resulted in a more complete review of proposals with the best projects being identified and selected for funding. It was also mentioned that the collaboration resulted in moving more technologies forward and creating new opportunities with industry, although there were inadequate metrics provided within the survey to assess or confirm this observation. For the CTSI-based product development teams, the key metrics monitored were meeting milestones, publication records, and follow-on funding. As an example, the University of Washington CTSI, the Institute of Translational Health Sciences (ITHS), reported a cumulative 23-fold return-on-investment for its small pilot fund program through the first 6 years of CTSA funding (personal communication, N. Disis). Also on a cumulative basis, the University of Rochester CTSI reported an 11-fold return on pilot funds awarded over the first 5 years of CTSA funding (personal communication, T. Fogg). For commercialization gap funds, the TTOs track whether the funding leads to additional invention disclosures, increased licensing opportunities, or to the formation of start-up companies.
Separate acceleration organizations
The taskforce interviewed and reviewed websites for five initiatives or organizations that were identified as a result of the survey or follow-on interviews. These organizations had variable levels of affiliations with the regional CTSI, ranging from complete integration to no integration.
Carolina Kickstart (CKS) is a core program of the UNC CTSI (NC TraCS) and was developed to provide support for faculty in commercializing biomedical technologies through startup generation. CKS educates faculty and students on the process of commercialization through company formation; funds promising technologies and emerging companies through a grant program and connects faculty with outside resources that can provide services, advice, funding, and management expertise. CKS also provides incubation services and expertise to earlystage companies.
The Alabama Drug Discovery Alliance (ADDA) is a built on an existing collaboration between the University of Alabama at Birmingham (UAB) School of Medicine (SOM), Southern Research Institute (SRI), the UAB Center for Clinical and Translational Science (CCTS), and the UAB Comprehensive Cancer Center (CCC). ADDA's objective is to facilitate drug discovery and development utilizing the resources in each institution. These resources include molecular target identification and validation, high through-put screening, iterative medicinal chemistry, preclinical toxicology and absorption, distribution, metabolism, and excretion (ADME) analysis, etc. Each project has a multidisciplinary project team built around it with members of both institutions, including a member of the TTO (UAB Research Foundation). The ADDA funds pilot projects that are at different stages of the drug discovery and development process, and provide an umbrella of services tailored to the needs of each faculty member and each project.
The Technology Commercialization Initiative (TCI) at Albert Einstein College of Medicine and Montefiore Medical Center was co-created by the Einstein CTSI (ICTR) and Albert Einstein College of Medicine's TTO to increase the number of invention disclosures and licensing opportunities at the Medical Center. The CTSI PI and/or the Director of the Office of Business Development spend time on a monthly basis at the Medical Center, encouraging the disclosure of innovative technologies for further development. The Einstein CTSI and TTO also work on early drug development initiatives through a pilot project initiative to enable new projects involving chemical genomics and structure-based compound design.
Biodesign (BD) at Stanford University has a mission to train students, fellows, and faculty in the "Biodesign Process:" a systematic approach to needs finding and the invention and implementation of new biomedical technologies. Key components of the program include fellowships; classes in medical technology innovation; mentoring of students and faculty in the technology transfer process; career services for students interested in medical technology careers; and community educational events. Biodesign works closely with the Stanford Office of Technology Licensing (OTL) as well as with Spectrum, the Stanford Center for Clinical and Translational Research and Education (CTSA recipient) to help accelerate the further development of the identified technologies in Biodesign into patient care by providing further mentoring and participating in the development and review of pilot programs.
Finally, UPstart at the University of Pennsylvania is an accelerator program out of their TTO and has no formal affiliation with their CTSI. The program supports technology commercialization by providing support to faculty to start new companies based on inventions and technology coming out of the institution. UPstart provides several services to faculty members, such as market analysis, identification of fund raising strategies, management team recruitment and partnership development, among others.
Discussion
Early medical product development is increasingly being pushed back into academic and nonprofit research settings as companies seek to reduce risks and bring down the cost of new product development, now estimated at over $1 billion for a single drug. 5, 6 Biopharmaceutical companies that were previously open to licensing of early-stage discoveries are now focusing their efforts on products that have been tested clinically. Similarly, venture capital firms are more likely to fund start-up companies that have clinical data (pre-phase 2) and a clearly defined regulatory path. 7 Thus, in order to compete effectively for research dollars and derisk projects for future investment, academic investigators must now be able to articulate viable commercialization, clinical, and regulatory strategies for their discoveries. A lack of expertise in product development or of access to the expertise required to move a product idea forward continues to be a significant obstacle for most academic investigators. 8, 9 NCATS is addressing these obstacles through intramural programs and extramural funding of the CTSA consortium, established, in part, to accelerate the translation of laboratory discoveries into treatments for patients and to train a new generation of clinical and translational researchers. The AWG developed this survey to explore these activities and the metrics that CTSIs are using to assess their success. Our assumption was that product development services and training provided by the CTSIs would complement the activities and the metrics of the TTOs. A goal of the survey was to identify examples of CTSI/TTO partnerships that might provide "best practice" models for CTSIs to consider.
The survey revealed that all of the responding institutions offer multiple product development services to their translational scientists. These opportunities range from nonspecific educational programs on medical product development and entrepreneurship to the creation of individual product teams following the model of the biotechnology and pharmaceutical industries. There are as many TTO-directed programs as CTSI-directed programs. The primary areas of overlap are in development consultation, pilot/gap funding, and facilitation of relationships with industry. The TTO-directed programs focus more on market assessments and commercialization efforts. In general, the prevalence of the TTO programs did not correlate with duration of CTSA funding or total institutional NIH funding levels. Two exceptions were noted; TTOs in institutions with lower levels of NIH funding were statistically more likely to conduct market assessments of product ideas and present them to commercialization workshops. This observation may reflect a greater reliance on the commercial sector for support of IP development within the institution, since many TTOs do not provide gap funding to their investigators. Similarly, institutions with higher levels of NIH funding may have more visibility in the business community, and therefore, may have less need to advertise their products externally.
The CTSI-directed programs were clearly newer in relation to the TTO-directed programs and more focused on the clinical and regulatory components of product development. Only two CTSIdirected programs correlated with total NIH funding levels, the presence of cGMP or GLP facilities to make and test product. These facilities all existed before the CTSA program and reflect a longerterm commitment to translational research at those institutions. The duration of CTSA funding appeared to be an important factor for many of the programs offered by CTSIs. Institutions that were early recipients of CTSA funds (2006) (2007) (2008) were more likely to support the nonclinical work required to move investigational products into clinical testing. This support included funds for preclinical proof-of-concept studies, support for IND and IDE applications to FDA, and identification of industry partners to help guide the development process. The fact that these programs are more common in the early CTSIs may reflect the growing need for these services as well as the time required to develop them. It is also possible that these institutions already had many of the programs available and were thus better positioned to apply for CTSA funds when the Request-for-Application first came out.
Surprisingly, only half of the CTSIs reported formal collaborative programs with their TTO, although all stated that more collaboration was desirable in order to ensure efficient utilization of gap funding and each others resources and expertise. The joint programs benefitted from early efforts by senior administrative officials and the CTSI principal investigators, who championed their development. The three most common programs were joint review of applications for gap commercialization funds, participation on advisory committees for development consultation, and joint participation on individual product development teams. An example of how one institution coordinates review and project support was provided. There was general belief among the CTSIs interviewed that the TTO collaborations resulted in the selection of the best projects for funding or more in-depth support; from both a commercialization and development feasibility standpoint.
Strikingly, many of the characteristics of the CTSI-TTO collaborative programs were similar to the CTSI-independent acceleration programs. Typically, early recognition by senior administration officials that acceleration or maturation of products would benefit the institution resulted in a fairly rapid and seamless initiation of the program. The degree of affiliation of these senior officials with the CTSI appeared to determine the extent to which these programs fell under the CTSI umbrella. For example, the initiator of Carolina Kickstart program was also the PI of the CTSI thus ensuring a tight connection between the CTSI and this accelerator program; whereas UpStart was initiated out of the TTO at the University of Pennsylvania and does not have a formal relationship with their CTSI. The programs supported by the CTSI-independent acceleration programs also included participatory advisory boards, commercialization and/ or translational gap funds and project development teams. One noted difference with the "CTSI-independent" initiatives was a greater involvement and/or access to external industry or VC expertise. This was perceived as one of the greatest advantages of the external acceleration programs.
In summary, this survey provides baseline information on the types of programs and services that have been developed by CTSIs and TTOs to support medical product development. The strength of the collaborations, when they exist, lies in combining TTO expertise in commercialization and market analysis with the CTSI expertise in medical product development, including guidance and support for the conduct of nonclinical and clinical studies, identification of a feasible regulatory approval path, and securing SBIR/STTR awards to faculty developing commercially promising technologies. In all cases, the joint programs benefitted from the expertise of current or former industry representatives. It was suggested that the success of these programs will ultimately be measured in licensing opportunities and new start-ups, although several respondents expressed a desire for improved metrics, such as follow-on development funding, number of IND or IDE submissions, or number of investigator-initiated clinical trials; all of which would likely precede licensing in the current technology environment. At present there is insufficient data in the survey or the published AUTM data to determine if joint programs are having the hoped-for impact on commercialization measures such as licenses and start-ups. Our data suggests that institutions with established CTSI-TTO collaborative programs have increased numbers of invention disclosures, health-related licenses and start-ups. While encouraging, there are many factors that could explain these results, collaborative programs being only one. Institutions are seeing high return-on-investment from the gap funding programs, indicating that they are successfully positioning preclinical work for further development.
Among those CTSIs not formally collaborating with their TTO there was apparent overlap in the services each provided, particularly in the area of development consultation and the selection of projects for gap or pilot funding. Since these translational research services are provided by different offices with distinct reporting structures (i.e., multiple handoff points), it is possible that the individual projects may not be managed optimally or that projects deemed marketable may not have straightforward development paths. This lack of integration suggests opportunities for greater synergy.
The survey data has some limitations that should be considered in interpreting the results. First, the response rate to the survey was 50% and there were limited numbers of institutions available for follow-on questions. Further, the views of those who did not respond to our survey might have differed from the views of respondents, leading to bias in our findings. In order to address the potential for bias, the survey team compared the responder and nonresponder institutions by two measures of translational research. These included the total 2012 NIH funding levels by institution and the duration of CTSA funding by institution. These comparisons showed no differences between the responder and nonresponder institutions (p > 1.0) and suggest that the data is representative of nonresponding institutions. Second, the survey respondents were either affiliated with the CTSI or the TTO, but typically not both. Although most respondents coordinated their survey responses with a representative of the partner organization, not all did, and therefore, some of the data may be incomplete. Third, our survey attempted to capture the impact of the joint programs by requesting data on the number of health-related invention disclosures and licenses to start-ups or established companies. Although we report a promising trend, the data were requested as ranges and therefore lack the precision needed to see real differences between institutions. A review of AUTM data confirmed that the numbers of invention disclosures and licenses are too small, and the duration of the CTSA programs too short, to draw meaningful conclusions about the long-term impact of joint CTSI-TTO programs on these commercialization measures. Furthermore, the AUTM data does not separate out health-related licenses from the total, something that could be captured prospectively by the CTSA and AUTM.
Conclusions
In conclusion, many CTSIs have formalized a working relationship with their TTO in hopes of bringing innovations closer to commercial readiness. These partnerships promise a more efficient use of limited development funds and a more in-depth vetting of the business opportunity and regulatory path to human testing. Our data suggest a model of collaboration based on three key elements; advisory boards with commercial and regulatory input, gap funding for preclinical proof-of-concept studies, and project teams with team management. We recommend that sites use the survey data to assess the status of their existing CTSI-TTO partnerships in order to identify additional programs that would ensure greatest synergy. Although our outcome data is limited, we anticipate that organizations with well-integrated programs will compete more effectively for translational research dollars by derisking their projects for future investment and/or licensing. We suggest additional metrics to assess the global impact of both the CTSI programs and the CTSI-TTO collaborations on commercialization of new medical products.
